A filing for a large offering of stock by existing shareholders doesn't help matters when considering an investment in the wine producer.
Something that should never go out of fashion is buying stocks with excellent potential for future gains.
This portfolio has returned 305.6% since its inception in 2007.
October could be as scary as September for market participants. Here's how I'm playing it.
Is Delta dying down, or is this the calm before the storm up north?
Investors are increasingly looking to the companies involved in clinical trials. Here are six favorite names in this space.
In a market with elevated valuations and low yields, we see pharmaceutical stocks as a respite from both.
The 2021 Tax Loss Selling Recovery Portfolio gave up ground over the last month yet continues to outperform key indices.
The current candidates for the 2022 Tax-Loss Selling Recovery Portfolio are few and far between, with only a couple households names in the bunch.
CAKE is the most mall-dependent of all restaurant stocks, according to a recent report.